Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 7/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449304 | 0.90 | CYP11B1 (0.38) | HTR3ACCKARIGF1RCYP11B1CYP11B2 | |
| SCHEMBL2450914 | 0.87 | CYP11B1 (0.39) | HTR3ACYP11B1CYP11B2ALPLPIK3CA | |
| SCHEMBL1075073 | 0.83 | PTGS1 (0.35) | ALDH1A1KDM4ENPC1MAPTRAB9A | |
| SCHEMBL1074021 | 0.82 | PTGS1 (0.35) | PIK3CACYP1A2 | |
| SCHEMBL2345314 | 0.80 | PIK3CA (0.38) | IGF1RALDH1A1KDM4EGAAPIK3CA | |
| SCHEMBL1074799 | 0.80 | GLA (0.39) | GAACYP1A2 | |
| SCHEMBL1071650 | 0.79 | CYP1A2 (0.35) | ALDH1A1CYP1A2 | |
| SCHEMBL2452818 | 0.78 | PIK3CA (0.41) | HTR3ACYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL1073998 | 0.78 | PDE4B (0.38) | CYP11B2 | |
| SCHEMBL19953120 | 0.75 | USP2 (0.38) | ALDH1A1PIK3CACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | claimed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | claimed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | claimed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | claimed |
| EP-2053044-A1 | Novel imidazole derivatives | Syngenta Participations AG (CH) | 2009-04-29 | — | — | EP | claimed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | claimed |
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| EP-2053044-A1 | Novel imidazole derivatives | Syngenta Participations AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | CBR3, C3AR1, C1R | HTR3A 2050/4885CCKAR 975/4885IGF1R 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.